BioCryst Pharmaceuticals, Inc. (BO1.F)

6,06 -0,10 (-1,66%) Börsenschluss: 08:10AM CEST

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 536

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jon P. Stonehouse	CEO, President & Executive Director	1,13M	595,12k	1961
Mr. Anthony J. Doyle	Senior VP, CFO & Interim Principal Accounting Officer	777,93k	N/A	1980
Ms. Alane P. Barnes	Senior VP, Chief Legal Officer & Corporate Secretary	730,87k	N/A	1966
Dr. Helen M. Thackray FAAP, M.D.	Chief Research & Development Officer	897,7k	N/A	1968
Mr. Charles K. Gayer	Senior VP & Chief Commercial Officer	730,29k	N/A	1971
Mr. John D. Bluth	Chief Communications Officer	N/A	N/A	1973
Ms. Stephanie Angelini	Chief People Officer	N/A	N/A	N/A
Dr. William P. Sheridan MBBS	Chief Development Officer & Interim Chief Medical Officer	721,07k	4,05M	1955
Dr. Yarlagadda S. Babu Ph.D.	Chief Discovery Officer	635,88k	1,15M	1953
Ms. Jinky Ang Rosselli	Chief Data & Insights Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Corporate Governance

BioCryst Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 6. Die grundlegenden Scores sind Audit: 9, Vorstand: 2, Shareholderrechte: 8, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.